Még nem toboroz
GLUTAMICS III
2024-513575-40-01· 3. fázis· Region Oestergoetland· Forrás
Még nem toboroz
Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism
NCT07816978· 4. fázis· Sahlgrenska University Hospital· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
NCT07584967· 2. fázis· AnaCardio AB· Forrás
Toboroz
A study to test the safety and efficacy of RBD1119 given by injection in participants with coronary artery disease
2026-525901-10-00· 2. fázis· Ribocure Pharmaceuticals AB· Forrás
Toboroz
A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00· 2. fázis· Ribocure Pharmaceuticals AB· Forrás
Toboroz
Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
2025-524722-17-00· 4. fázis· Region Skane· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Toboroz
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· 3. fázis· Charite University, Berlin, Germany· Forrás
Még nem toboroz
Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma
2026-526821-16-00· 1/2. fázis· Karolinska University Hospital· Forrás
Toboroz
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic
Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
2025-524793-42-00· 2. fázis· Janssen Cilag International· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Még nem toboroz
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· 2. fázis· Oslo Universitetssykehus HF· Forrás
Toboroz
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
NCT07514858· 2. fázis· H. Lundbeck A/S· Forrás
Toboroz
Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa
NCT07169747· 2. fázis· Region Skane· Forrás
Toboroz
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· 3. fázis· Boehringer Ingelheim· Forrás
Még nem toboroz
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· 3. fázis· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Forrás
Toboroz
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952· 3. fázis· Bayer· Forrás
Még nem toboroz
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
2025-524014-29-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
2025-524022-18-00· 2. fázis· Vaestra Goetalandsregionen· Forrás
Még nem toboroz
An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2024-519811-32-00· 4. fázis· Region Oestergoetland· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial
2025-521686-27-01· 2. fázis· Region Uppsala· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa
2024-515172-12-00· 2. fázis· Xinnate AB· Forrás
Toboroz
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00· 2. fázis· Klinikum der Universitaet Muenchen AöR· Forrás
Toboroz
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805· 3. fázis· Bayer· Forrás
Toboroz
The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients with Peritoneal Metastasis
2024-514879-17-00· 3. fázis· Karolinska University Hospital· Forrás
Fut, nem toboroz
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· 2/3. fázis· Bristol-Myers Squibb· Forrás
Még nem toboroz
The REFINE study
2025-522133-66-00· 3. fázis· Karolinska University Hospital· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
NCT06184659· 4. fázis· Scandinavian Critical Care Trials Group· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Fut, nem toboroz
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136· 3. fázis· AstraZeneca· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
2024-519593-39-00· 3. fázis· Karolinska University Hospital· Forrás
Toboroz
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7
2023-508196-36-00· 2. fázis· Karolinska University Hospital· Forrás
Toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Thrombolysis in Factor Xa-inhibitors Trial
NCT06878066· 3. fázis· Guri Hagberg· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Showing 50 of 147.